Core Viewpoint - Zhejiang Securities Regulatory Bureau issued regulatory warnings to Minsheng Securities and two sponsoring representatives due to violations during the continuous supervision of Zhejiang Weikang Pharmaceutical's IPO process [1] Group 1: Violations Identified - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects, indicating insufficient verification procedures [1] - The conclusions drawn in the continuous supervision documents for Weikang Pharmaceutical's 2023 annual report were not cautious enough, revealing deficiencies in internal controls within the investment banking operations [1] Group 2: Regulatory Framework - The actions of Minsheng Securities violated Article 5, Paragraph 1 of the "Administrative Measures for Sponsoring Business of Securities Issuance and Listing" (CSRC Order No. 170) [1] - The sponsoring representatives, Ren Shaozhong and Zhong Desong, bear primary responsibility for the aforementioned violations [1]
民生证券及两名保代被出具警示函